Wegovy approved for cutting cardiovascular disease risk The TGA has approved semaglutide (sold as Wegovy) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in overweight and obese adults.
Examining the pros and cons of semaglutide A new study finds lowered risk of 42 health outcomes and increased risk of 19 for people using GLP-1RAs, highlighting the ‘far-reaching potential’ of the drugs.
In Practice: EOIs to join ATAGI Australia’s immunisation advisory group is seeking applications for new members to provide advice to the Federal Health Minister.
Ozempic shortage extended The manufacturer has informed the TGA that supply will be limited until 31 December 2025, with GPs labelling it an ‘ongoing disappointment’.
TGA urges ‘extreme caution’ amid fake Ozempic pen imports GPs are being warned to lookout for the counterfeit pens and are urged to inform their patients, with one person already suffering life-threatening complications.
Mounjaro expanded to include weight management The TGA has approved tirzepatide for the treatment of overweight and obesity for those with comorbidities, via private prescription.
Study links semaglutide and suicidal ideation risk There are calls for urgent investigation into its impact on mental health, but GPs are urging caution when interpreting the research.
PBS restrictions placed on diabetes medicines GPs now need to gain additional approval prior to starting patients on all GLP-1 RAs, including semaglutide.
Study links Ozempic to kidney failure prevention It found semaglutide reduced risk of major kidney events by 24% for type 2 diabetes patients, but GPs have urged caution.
Replica Ozempic and Mounjaro to be banned The Government has removed a loophole allowing the mass production of the compounded drugs amid growing patient safety concerns.